AVDL — Avadel Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.57bn
- $1.46bn
- $27.96m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -33.2 | 7.03 | -77.3 | -137 | -160 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 9.23 | -35.7 | 11.2 | 15.1 | 33 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -10.5 | -14.3 | 3.69 | 24.5 | -3 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -38.3 | -48.7 | -77.3 | -70.3 | -129 |
Capital Expenditures | -0.029 | -0.098 | -0.026 | -0.716 | 0 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 38.8 | -69.6 | 57 | 80.4 | -50.1 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 38.7 | -69.7 | 56.9 | 79.7 | -50.1 |
Financing Cash Flow Items | -0.145 | 0 | — | -4.8 | 25.6 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.027 | 180 | 0.263 | 14.5 | 135 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.449 | 61.9 | -21 | 23.3 | -42.8 |